Grant: Operating Grant
McGill University
$319,820.00
Signal, Safety, and Success: An Analysis of Risk, Benefit, and Translation after Detection of Clinical Activity in Drug Development
FY 2011-12
Summary
The vast majority of new drugs entered into clinical development never show adequate safety and efficacy. As a result, many patients are harmed and resources spent in failed trials. This grant is aimed at discovering whether there are ways to better protect patients, learn from failure, and save resources during drug development. Our preliminary research shows that drug developers often run trials that are based on guesswork or biased evidence; when this occurs, studies can fail and patients are harmed. We want to determine how frequently drug developers run drug trials based on good clinical evidence, and measure the impact of good evidence in terms of improving patient outcomes in trials and increasing the chances that a drug will later prove effective and safe.
Department
Program
Operating Grant
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
238820
Name
Kimmelman Jonathan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Biomedical
Prcname2
Humanities, Social Sciences, Law & Ethics in Health
Projecttitle
Signal, Safety, and Success: An Analysis of Risk, Benefit, and Translation after Detection of Clinical Activity in Drug Development
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$319,820
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Knowledge Translation; Medical Evidence; Pharmaceutical Development; Phase 2 Trials; Research Ethics; Research Integrity; Risk; Systematic Reviews; Translational Research; Validity
Abstract
The vast majority of new drugs entered into clinical development never show adequate safety and efficacy. As a result, many patients are harmed and resources spent in failed trials. This grant is aimed at discovering whether there are ways to better protect patients, learn from failure, and save resources during drug development. Our preliminary research shows that drug developers often run trials that are based on guesswork or biased evidence; when this occurs, studies can fail and patients are harmed. We want to determine how frequently drug developers run drug trials based on good clinical evidence, and measure the impact of good evidence in terms of improving patient outcomes in trials and increasing the chances that a drug will later prove effective and safe.
Competitiondate
201109
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Kimmelman, Jonathan
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $319,820~ $0~